(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANÁLOGO DE SANGLIFERINA, COMBINAÇÃO, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA TRATAMENTO DE UM SUJEITO SOFRENDO DE CÂNCER OU DE MALIGNIDADE DE CÉLULA-B

ArquivadaInvention PatentPCT · EP2017079549

Application data

Number

112019009903

Type

Invention Patent

Filing

11/17/2017

Publication

08/13/2019

PCT

EP2017079549

Progress at the INPI

  1. Filing11/17/17
  2. Publication08/13/19
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 11/17/2017 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 10/05/2021. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

NEUROVIVE PHARMACEUTICAL AB

SE

See this company's full portfolio

Inventors

A. G. (pessoa física)

SE

M. H. (pessoa física)

SE

M. G. (pessoa física)

GB

S. M. (pessoa física)

GB

Technical data

IPC Classification

Priority claims

DK

PA 2016 70920 · 11/18/2016

DK

PA 2017 70054 · 01/30/2017

Abstract

A presente invenção refere-se aos usos de análogos macrocíclicos de sangliferina no tratamento de câncer, especialmente de câncer de fígado.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Adição na publicação

#15.35

10/05/2021

RPI 2648

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

05/11/2021

RPI 2627

Arquivamento - Art. 33 da LPI

#11.1

02/23/2021

RPI 2616

Notificação de entrada na fase nacional - PCT

#1.3

08/13/2019

RPI 2536

Alteração de dados cadastrais

#1.1

05/28/2019

RPI 2525

Related

From the same holder

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.